Fisher & Paykel Healthcare Corporation Ltd banner

Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH

Watchlist Manager
Fisher & Paykel Healthcare Corporation Ltd Logo
Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH
Watchlist
Price: 35.98 NZD -0.74% Market Closed
Market Cap: NZ$21.1B

P/OCF

37.6
Current
6%
Cheaper
vs 3-y average of 40.1

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
37.6
=
Market Cap
NZ$23.4B
/
Operating Cash Flow
NZ$561.4m

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
37.6
=
Market Cap
NZ$23.4B
/
Operating Cash Flow
NZ$561.4m

Valuation Scenarios

Fisher & Paykel Healthcare Corporation Ltd is trading below its 3-year average

If P/OCF returns to its 3-Year Average (40.1), the stock would be worth NZ$38.31 (6% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-74%
Maximum Upside
+6%
Average Downside
32%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 37.6 NZ$35.98
0%
3-Year Average 40.1 NZ$38.31
+6%
5-Year Average 39 NZ$37.27
+4%
Industry Average 9.8 NZ$9.33
-74%
Country Average 13.9 NZ$13.25
-63%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
NZ
Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH
21.1B NZD 37.6 48.4
US
Intuitive Surgical Inc
NASDAQ:ISRG
171.2B USD 56.5 60
US
Abbott Laboratories
NYSE:ABT
158.3B USD 16.5 25.2
US
Stryker Corp
NYSE:SYK
125.3B USD 24.8 38.6
IE
Medtronic PLC
NYSE:MDT
106.9B USD 14.7 23.2
US
Boston Scientific Corp
NYSE:BSX
92B USD 20.3 25.8
DE
Siemens Healthineers AG
XETRA:SHL
40B EUR 13.2 18.9
US
Edwards Lifesciences Corp
NYSE:EW
48.9B USD 30.6 44.6
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.1B USD 38.2 42.6
US
Becton Dickinson and Co
NYSE:BDX
43.3B USD 12.8 24.7
US
Resmed Inc
NYSE:RMD
32B USD 16.7 21.6

Market Distribution

Higher than 87% of companies in New Zealand
Percentile
87th
Based on 224 companies
87th percentile
37.6
Low
1.5 — 8.1
Typical Range
8.1 — 20.7
High
20.7 —
Distribution Statistics
New Zealand
Min 1.5
30th Percentile 8.1
Median 13.9
70th Percentile 20.7
Max 325.4

Fisher & Paykel Healthcare Corporation Ltd
Glance View

Nestled in the heart of New Zealand, Fisher & Paykel Healthcare Corporation Ltd. has emerged as a formidable player in the global healthcare market, largely due to its innovative spirit and relentless focus on respiratory care solutions. Originally part of Fisher & Paykel Industries, the healthcare division carved its own path in 2001, quickly becoming synonymous with high-quality medical devices. The company’s journey can be compared to a constant rhythm of innovation, particularly in areas that address obstructive sleep apnea, acute respiratory distress, and surgical humidification. Its revenue streams are primarily bolstered by a diverse array of products, including sleep apnea masks, humidifier systems for intensive care units, and related respiratory accessories. These offerings are not just technological marvels but are designed to improve patient outcomes and their quality of life, which resonates well with healthcare providers worldwide. Over the years, Fisher & Paykel Healthcare has strategically expanded its operations beyond its Kiwi roots, anchoring its presence in over 120 countries. This global footprint, coupled with a robust pipeline of patented products, enables sustained revenue growth and stability. The company’s financial health is driven by a business model that emphasizes research and development, ensuring that it remains at the forefront of medical innovation. By fostering close relationships with healthcare professionals and institutions, Fisher & Paykel not only gains invaluable insights to refine its products but also cultivates a loyal customer base. This enduring approach cements its position not only as a leader in the healthcare sector but also as a trusted partner in the critical mission to enhance patient care worldwide.

FPH Intrinsic Value
25.07 NZD
Overvaluation 30%
Intrinsic Value
Price NZ$35.98
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett